Literature DB >> 3106350

Characterization of carrier-mediated transport systems for small neutral amino acids in human fibroblast lysosomes.

R L Pisoni, K S Flickinger, J G Thoene, H N Christensen.   

Abstract

Analog inhibition studies of the uptake of proline, serine, and threonine into human fibroblast lysosomes, purified on Percoll gradients, reveal the presence of three new transport systems. These systems fail to show the Na+ requirement usual for the plasma membrane. Proline uptake into fibroblast lysosomes occurs mainly by two routes: a predominant route half-saturating at 0.01 mM, and a lower-affinity route, half-saturating at 0.07 mM. The latter so far appears specific for L-proline and its 3,4-dehydro derivative. The high affinity route has a broad scope, recognizing best, beyond these two amino acids, various unbranched neutral amino acids not over 5 carbons long. Neither system accepts to a significant extent D-proline, hydroxyproline, cationic or anionic amino acids, nor neutral ones with bulky side chains. 2-Aminoisobutyrate and its N-methyl derivative have little effect on proline uptake, in contrast to their effectiveness on its uptake by the intact fibroblast. The rate of lysosomal proline uptake maximizes at about pH 6.4, is inversely related to the osmolarity of the medium, and is unaffected by the extralysosomal presence of MgATP. The competition among alanine, serine, and threonine points to sharing of the broad-scope system for proline, although the main part of their uptake occurs by a third route that rejects amino acids in which the alpha-amino group is methylated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106350

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Identification and characterization of a lysosomal transporter for small neutral amino acids.

Authors:  C Sagné; C Agulhon; P Ravassard; M Darmon; M Hamon; S El Mestikawy; B Gasnier; B Giros
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

2.  Intracellular localization of p40, a protein identified in a preparation of lysosomal membranes.

Authors:  Marielle Boonen; Isabelle Hamer; Muriel Boussac; Anne-Françoise Delsaute; Bruno Flamion; Jérôme Garin; Michel Jadot
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

Review 3.  Molecular physiology and pathophysiology of lysosomal membrane transporters.

Authors:  C Sagné; B Gasnier
Journal:  J Inherit Metab Dis       Date:  2008-04-15       Impact factor: 4.982

Review 4.  Neutral amino acid transport systems in animal cells: potential targets of oncogene action and regulators of cellular growth.

Authors:  M H Saier; G A Daniels; P Boerner; J Lin
Journal:  J Membr Biol       Date:  1988-08       Impact factor: 1.843

5.  Non-physiological amino acid (NPAA) therapy targeting brain phenylalanine reduction: pilot studies in PAHENU2 mice.

Authors:  Kara R Vogel; Erland Arning; Brandi L Wasek; Teodoro Bottiglieri; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-09-14       Impact factor: 4.982

6.  Has the basic metabolic defect of cystinosis been discovered?

Authors:  J A Schneider
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

7.  Demonstration of adenosine deaminase activity in human fibroblast lysosomes.

Authors:  E R Lindley; R L Pisoni
Journal:  Biochem J       Date:  1993-03-01       Impact factor: 3.857

8.  N-acetyl-D-glucosamine countertransport in lysosomal membrane vesicles.

Authors:  A J Jonas; H Jobe
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

9.  Defective glucuronic acid transport from lysosomes of infantile free sialic acid storage disease fibroblasts.

Authors:  H J Blom; H C Andersson; R Seppala; F Tietze; W A Gahl
Journal:  Biochem J       Date:  1990-06-15       Impact factor: 3.857

10.  Mechanism of acyclovir uptake in rat jejunum.

Authors:  K C Meadows; J B Dressman
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.